[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3319997A4 - Hepatitis c virus immunogenic compositions and methods of use thereof - Google Patents

Hepatitis c virus immunogenic compositions and methods of use thereof Download PDF

Info

Publication number
EP3319997A4
EP3319997A4 EP16820906.2A EP16820906A EP3319997A4 EP 3319997 A4 EP3319997 A4 EP 3319997A4 EP 16820906 A EP16820906 A EP 16820906A EP 3319997 A4 EP3319997 A4 EP 3319997A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
methods
immunogenic compositions
virus immunogenic
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16820906.2A
Other languages
German (de)
French (fr)
Other versions
EP3319997A1 (en
Inventor
Michael Houghton
John L. LAW
Michael Logan
Darren HOCKMAN
Abdolamir LANDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of EP3319997A1 publication Critical patent/EP3319997A1/en
Publication of EP3319997A4 publication Critical patent/EP3319997A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16820906.2A 2015-07-07 2016-07-06 Hepatitis c virus immunogenic compositions and methods of use thereof Pending EP3319997A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189657P 2015-07-07 2015-07-07
PCT/IB2016/001051 WO2017006182A1 (en) 2015-07-07 2016-07-06 Hepatitis c virus immunogenic compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3319997A1 EP3319997A1 (en) 2018-05-16
EP3319997A4 true EP3319997A4 (en) 2019-01-23

Family

ID=57686164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16820906.2A Pending EP3319997A4 (en) 2015-07-07 2016-07-06 Hepatitis c virus immunogenic compositions and methods of use thereof

Country Status (5)

Country Link
US (4) US10300131B2 (en)
EP (1) EP3319997A4 (en)
CA (1) CA2986342C (en)
HK (1) HK1255379A1 (en)
WO (1) WO2017006182A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229414A (en) * 2015-10-08 2023-12-15 艾伯塔大学理事会 Hepatitis C virus E1/E2 heterodimer and method for producing the same
EP3515483A4 (en) * 2016-09-21 2020-12-16 The Governors of the University of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
EP3618859A4 (en) * 2017-04-27 2021-05-05 Vanderbilt University Hepatitis c virus gene sequences and methods of use therefor
AU2019233861A1 (en) * 2018-03-16 2020-10-01 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081848A2 (en) * 2006-01-04 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
WO2014067498A1 (en) * 2012-11-05 2014-05-08 Centro De Ingenieria Genetica Y Biotecnologia Chimeric vaccine antigens against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
JP4458556B2 (en) 1997-05-06 2010-04-28 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Intracellular production of hepatitis C E2 truncated polypeptide
CA2661492A1 (en) 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081848A2 (en) * 2006-01-04 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
WO2014067498A1 (en) * 2012-11-05 2014-05-08 Centro De Ingenieria Genetica Y Biotecnologia Chimeric vaccine antigens against hepatitis c virus
EP2915544A1 (en) * 2012-11-05 2015-09-09 Centro De Ingenieria Genetica Y Biotecnologia Chimeric vaccine antigens against hepatitis c virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FOURNILLIER A ET AL: "Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 9, 1 September 1999 (1999-09-01), pages 7497 - 7504, XP002191425, ISSN: 0022-538X *
LOK MAN JOHN LAW ET AL: "Progress towards a hepatitis C virus vaccine", EMERGING MICROBES & INFECTIONS, vol. 2, no. 11, 20 November 2013 (2013-11-20), pages e79, XP055319255, ISSN: 2222-1751, DOI: 10.1038/emi.2013.79 *
MICHAEL LOGAN ET AL: "Native Folding of a Recombinant gpE1/ gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG", JOURNAL OF VIROLOGY., vol. 91, no. 1, 1 January 2017 (2017-01-01), US, pages 1 - 13, XP055521292, ISSN: 0022-538X, DOI: 10.1128/JVI.01552-16 *
SEONG Y R ET AL: "Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 20-22, 6 April 2001 (2001-04-06), pages 2955 - 2964, XP027322013, ISSN: 0264-410X, [retrieved on 20010406] *
VALENTINA BOTTI ET AL: "The Hepatitis C Virus E1 Glycoprotein Undergoes Productive Folding but Accelerated Degradation When Expressed as an Individual Subunit in CHO Cells", PLOS ONE, vol. 6, no. 8, 17 August 2011 (2011-08-17), pages e23838, XP055535375, DOI: 10.1371/journal.pone.0023838 *

Also Published As

Publication number Publication date
US11576967B2 (en) 2023-02-14
US20180169219A1 (en) 2018-06-21
CA2986342C (en) 2024-04-02
CA2986342A1 (en) 2017-01-12
US10300131B2 (en) 2019-05-28
US10881727B2 (en) 2021-01-05
WO2017006182A1 (en) 2017-01-12
HK1255379A1 (en) 2019-08-16
EP3319997A1 (en) 2018-05-16
US20190224308A1 (en) 2019-07-25
US12005116B2 (en) 2024-06-11
US20230310590A1 (en) 2023-10-05
US20210100895A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
HK1255502A1 (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
IL257384A (en) Rnai-containing compositions and use of same for treating hepatitis b virus infection
EP3325097A4 (en) Compositions and agents against hepatitis b virus and uses thereof
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
IL244431A0 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
IL247309A0 (en) Compositions for the inactivation of virus replication and methods of making and using the same
EP3344291A4 (en) Vaccine compositions having improved stability and immunogenicity
EP3303571A4 (en) Live-attenuated virus and methods of production and use
EP3305310A4 (en) Oncolytic virus formulation and preparation method thereof
EP3341017A4 (en) Immunomodulatory compositions and methods of use thereof
EP3166615A4 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
EP3387119A4 (en) Improved compositions and methods for viral delivery of neoepitopes and uses thereof
IL240227A0 (en) Immunogenic compositions comprising silicified virus and methods of use
EP3194595A4 (en) Viral rna segments as immunomodulatory agents and vaccine components
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
EP3515483A4 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
EP3364986A4 (en) Plasma compositions and methods of use thereof
EP3137078A4 (en) Treatment of hepatitis delta virus infection
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
EP3416978A4 (en) Multivalent hiv vaccine boost compositions and methods of use
EP3226973A4 (en) Treatment of hepatitis delta virus infection
EP3169699A4 (en) Cancer vaccine compositions and methods of use thereof
EP3236997A4 (en) Dengue virus vaccine compositions and methods of use thereof
EP3423051A4 (en) Compositions and methods for treatment of influenza virus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/295 20060101ALI20181220BHEP

Ipc: A61P 37/04 20060101ALI20181220BHEP

Ipc: C07K 19/00 20060101AFI20181220BHEP

Ipc: C07K 1/14 20060101ALI20181220BHEP

Ipc: A61K 39/29 20060101ALI20181220BHEP

Ipc: A61K 39/12 20060101ALI20181220BHEP

Ipc: C12N 15/861 20060101ALI20181220BHEP

Ipc: A61P 31/14 20060101ALI20181220BHEP

Ipc: A61P 31/04 20060101ALI20181220BHEP

Ipc: A61K 39/00 20060101ALI20181220BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255379

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS